中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

43 records (took 0.028 seconds)

    감귤류과피추출액을포함하는아실코에이:콜레스테롤-오르토-아실트랜스퍼레이즈저해제조성물
    23.
    发明授权
    감귤류과피추출액을포함하는아실코에이:콜레스테롤-오르토-아실트랜스퍼레이즈저해제조성물 失效
    ACYL COA：包含CITRUS PEEL提取物的胆固醇-O-亚氨基转移酶抑制剂组合物

    公开(公告)号：KR100258584B1

    公开(公告)日：2000-07-01

    申请号：KR1019970055580

    申请日：1997-10-28

    Applicant: 한국과학기술연구원

    Inventor： 복성해 ,  정태숙 ,  권병목 ,  김영국 ,  배기환 ,  최명숙 ,  권용국 ,  안정아 ,  손광희 ,  최도일 ,  김성욱 ,  박용복 ,  황인규 ,  문석식 ,  이은숙

    IPC: A61K36/752 ,  A61P9/00

    Abstract: PURPOSE: A composition containing orange peel extract for inhibition of acyl CoA:cholesterol-O-acyltransferase(ACAT) is provided, which is useful for preventing and treating various cardiovascular diseases by decreasing blood low density lipoprotein(LDL) cholesterol. CONSTITUTION: A process fro the preparation of composition containing orange peel extract for inhibition of acyl CoA:cholesterol-O-acyltransferase(ACAT) comprises the steps of: washing the peel of tangerine originated in Korea, and drying at normal temperature to get Aurantii Nobilis Pericarpium; adding 95% ethanol, keeping at normal temperature for 24hours, and filtering to get extract and solid residue; extracting the solid residue twice more by the same process, and gathering extracts altogether; and concentrating the extract using a rotary vacuum evaporator under decompression to get concentrated extract containing bio-flavonoids.

    Abstract translation: 目的：提供含有抑制酰基CoA：胆固醇-O-酰基转移酶（ACAT）的橙皮提取物的组合物，其可用于通过降低血液低密度脂蛋白（LDL）胆固醇来预防和治疗各种心血管疾病。 构成：含有橙皮提取物抑制酰基CoA：胆固醇-O-酰基转移酶（ACAT）的组合物的制备方法包括以下步骤：洗涤起始于韩国的橘皮，并在常温下干燥以得到Aurantii Nobilis Pericarpium; 加入95％乙醇，在常温保持24小时，过滤得到提取物和固体残渣; 通过相同的方法提取固体残渣两次，并收集提取物; 并在减压下使用旋转式真空蒸发器浓缩提取物，得到含有生物黄酮的浓缩提取物。

    디오스민을포함하는동맥경화증및고지혈증의예방및치료용조성물
    24.
    发明公开
    디오스민을포함하는동맥경화증및고지혈증의예방및치료용조성물 失效
    组合物包含用于预防和治疗高脂血症和类风湿性关节炎的狄莫明

    公开(公告)号：KR1020000019719A

    公开(公告)日：2000-04-15

    申请号：KR1019980037962

    申请日：1998-09-15

    Applicant: 한국과학기술연구원

    Inventor： 복성해 ,  정태숙 ,  배기환 ,  박용복 ,  최명숙 ,  문석식 ,  권용국 ,  이은숙 ,  현병화 ,  최양규 ,  이철호 ,  안병태 ,  이새봄

    IPC: A61K31/70

    CPC classification number: A23L33/10 ,  A23C9/152 ,  A23V2002/00 ,  A23V2200/3262 ,  A61K31/7048

    Abstract: PURPOSE: A pharmaceutical composition and a functional food comprising diosmin are provided, for treating and preventing hyper lipidemia and arteriosclerosis. CONSTITUTION: The pharmaceutical composition comprises diosmin in effective amount; and pharmaceutically acceptable carriers. The functional food comprises 0.01-10 wt%, preferably 0.1-5 wt% of diosmin. Diosmin inhibits HMG CoA (3-hydroxy-3-methylglutaryl coenzyme) being a reduction enzyme which relates to the biosynthesis of cholesterol and ACAT (acyl CoA; cholesterol-O-acyltransferase) which transforms cholesterol into cholesteryl ester, and reduces the concentration of cholesterol in blood and neutral lipids. Also diosmin strongly inhibits the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface.

    Abstract translation: 目的：提供药物组合物和包含diosmin的功能性食品，用于治疗和预防高脂血症和动脉硬化。 构成：药物组合物含有有效量的diosmin; 和药学上可接受的载体。 功能性食品包含diosmin的0.01-10重量％，优选0.1-5重量％。 Diosmin抑制作为还原酶的HMG CoA（3-羟基-3-甲基戊二酰辅酶），其涉及将胆固醇转化为胆固醇酯的胆固醇和ACAT（酰基辅酶A;胆固醇-O-酰基转移酶）的生物合成，并降低胆固醇的浓度 在血液和中性脂质中。 此外，diosmin还强烈地抑制巨噬细胞 - 脂质复合物沉积或吸附到试验表面。

    루틴 및 쿼세틴을 포함하는 고지혈증, 동맥경화증 및 간 질환의예방 및 치료용 조성물
    25.
    发明公开
    루틴 및 쿼세틴을 포함하는 고지혈증, 동맥경화증 및 간 질환의예방 및 치료용 조성물 无效
    包含用于预防和治疗高脂血症，肠梗塞和肝病的RUTIN和QUERCETIN的组合物

    公开(公告)号：KR1020000019717A

    公开(公告)日：2000-04-15

    申请号：KR1019980037959

    申请日：1998-09-15

    Applicant: 한국과학기술연구원

    Inventor： 복성해 ,  정태숙 ,  배기환 ,  박용복 ,  최명숙 ,  문석식 ,  권용국 ,  이은숙 ,  이준성 ,  현병화 ,  최양규 ,  이철호 ,  안병태 ,  이새봄

    IPC: A61K31/70

    CPC classification number: A23L2/52 ,  A21D2/14 ,  A23C9/13 ,  A23C9/152 ,  A23L7/109 ,  A23L13/428 ,  A23L23/00 ,  A23L27/63 ,  A61K31/70 ,  Y10S514/824 ,  A61K2300/00

    Abstract: PURPOSE: A pharmaceutical composition and a functional food comprising bioflavonoids are provided, for treating and preventing hyper lipidemia, arteriosclerosis and a liver disease. CONSTITUTION: The pharmaceutical composition comprises rutin, quercetin or their mixture ineffective amount; and pharmaceutically acceptable carriers. The functional food comprises 0.01-10 wt% of rutin, quercetin or their mixture. Rutin can be obtained from a fruit, a leaf, a trunk and a flower of buck wheat and be used in the form of a powder or an extract. Rutin and quercetin being bioflavonoids inhibit HMG CoA (3-hydroxy-3-methylglutaryl coenzyme) being a reduction enzyme which relates to the biosynthesis of cholesterol and ACAT (acyl CoA; cholesterol-O-acyltransferase) which transforms cholesterol into cholesteryl ester in the body. Therefore rutin and quercetin reduce the concentration of cholesterol in blood, inhibit strongly a macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface, and protect a liver.

    Abstract translation: 目的：提供包含生物类黄酮的药物组合物和功能性食品，用于治疗和预防高脂血症，动脉硬化和肝脏疾病。 构成：药物组合物含有芦丁，槲皮素或其混合物无效量; 和药学上可接受的载体。 功能性食品包含0.01-10重量％的芦丁，槲皮素或其混合物。 芦丁可以从水果，叶子，树干和小麦花中获得，并以粉末或提取物的形式使用。 芦丁和槲皮素是生物类黄酮抑制作为还原酶的HMG CoA（3-羟基-3-甲基戊二酰辅酶），其涉及胆固醇和ACAT（酰基CoA;胆固醇-O-酰基转移酶）的生物合成，其将胆固醇转化为身体中的胆固醇酯 。 因此，芦丁和槲皮素降低血液中胆固醇的浓度，强烈地抑制巨噬细胞 - 脂质复合物沉积或吸附到试验表面，并保护肝脏。

Patent Agency Ranking